Q-omics provides the consensus-scored ABHD17AP5 profile across patient tissues and cancer cell-line models. ABHD17AP5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, ABHD17AP5 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, ABHD17AP5 RNA expression shows 11,486 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ESCA, KIRC, and ACC as cancer lineages where ABHD17AP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABHD17AP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABHD17AP5 survival associations across molecular data types. ABHD17AP5 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABHD17AP5 RNA expression–survival associations across cancer types. High ABHD17AP5 expression shows unfavorable associations in UVM, but favorable associations in ESCA, SKCM, UCEC, LUAD and READ. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify ESCA as the clearest survival context for ABHD17AP5 RNA expression.
This table summarizes ABHD17AP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ABHD17AP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABHD17AP5 shows higher tumor expression in KIRC, KIRP and LIHC. The KIRC box plot shows higher ABHD17AP5 RNA expression in tumor versus normal tissue (log2 FC = +0.228, t-test p < 0.001).
This table shows molecular features associated with ABHD17AP5 in patient tissues and cancer cell lines. In patient samples, ABHD17AP5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
